ZURA
What one share of Zura Bio holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with significant unmet medical need.
Zura Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.80 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.61 |
| Cash and investments | $2.15 |
| Book value | $2.07 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$2.09 | — | −$0.46 | — | $1.36 |
| 2024 | — | −$0.60 | $0.00 | −$0.38 | — | $2.25 |
| 2025 | — | −$1.06 | $0.00 | −$0.69 | — | $1.38 |